Source: Annual Congress 2005 - Lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Dworakowska, A. Kulwas, M. Lapinski, D. Tomaszewski, R. Dworakowski, J. Skokowski, E. Zekanowska, D. Rosc, E. Czestochowska (Gdansk, Bydgoszcz, Poland). Thrombin activatable fibrinolytic inhibitor in sera from NSCLC patients. Eur Respir J 2005; 26: Suppl. 49, 667

Member's Comments

No comment yet.

Related content which might interest you: Increased intraalveolar levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with interstitial lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 586s Year: 2002 Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) by lung cancer cell lines Source: Eur Respir J 2002; 20: Suppl. 38, 585s Year: 2002 Intraalveolar levels of tenascin C and thrombin-activatable fibrinolysis inhibitor in interstitial lung diseases Source: Eur Respir J 2003; 22: Suppl. 45, 83s Year: 2003 Role of thrombin-activatable fibrinolysis inhibitor in bronchial asthma Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009 Role of thrombin-activatable fibrinolysis inhibitor in lipopolysaccharide-induced acute lung injury Source: Annual Congress 2011 - Experimental modulation of airway inflammation Year: 2011 Proteinase inhibition regulates the anti-tumor activity of PAI-1 towards lung and prostate cancer cells Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Elevated endogenous thrombin potential in patients with lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 199s Year: 2003 Usefulness of selective neutrophil elastase inhibitor, sivelestat, in ALI patients with SIRS Source: Annual Congress 2012 - How to use technology to provide better critical care Year: 2012 Plasminogen activator inhibitor type 1 (PAI-1) is a negative regulator of lung cancer cells growth due to its anti-proteinase activity Source: Annual Congress 2008 - Novel targets in the molecular pathology of lung cancer and COPD Year: 2008 Secretory leukocyte proteinase inhibitor in lung cancer: an immunohistochemical and serological study Source: Eur Respir J 2006; 28: Suppl. 50, 388s Year: 2006 Proapoptotic and anti-proliferative effect of the stable plasminogen activator inhibitor type 1 (PAI-1) mutant on the lung cancer and endothelial cells Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009 Antithrombin plus alpha–1 protease inhibitor does not affect pulmonary inflammation and coagulation in a ‘double-hit’ lung injury model Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018 In vitro and in vivo characterisation of the novel neutrophil elastase inhibitor BI 1323495 Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020 Circulating d-Dimer lysozyme and angiotensin-converting enzyme in active sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 196s Year: 2001 Development of a novel immunoassay for the measurement of active plasmin in patients with IPF Source: International Congress 2017 – Chronic airway disease: markers of disease impact Year: 2017 5-lipoxygenase inhibitor therapy in IPF Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of nonsmall cell lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009 The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018 LSC Abstract – A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: International Congress 2015 – Immunomodulation: basic science and clinical aspects Year: 2015